OWC Pharmaceutical Research Corp. received a new permit from the Israel Medical Cannabis Agency to proceed with the safety study of their oral disintegrating tablet. The study protocol will be submitted to the Institutional Review Board [IRB] at a leading Israeli academic hospital in the coming weeks. The study is scheduled to start in second quarter 2018. In October of 2016 OWC announced that it had completed the development of a proprietary cannabinoid-enriched sublingual tablet for the administration of medical cannabis. The Tablet constitutes a smoke-free alternative for patients using medical cannabis. The technology behind the Tablet is protected and provides for the ingestion of virtually any dosage of medical cannabis with a sublingual delivery mechanism, whereby the compounds are absorbed directly into the patient’s blood through the oral epithelial tissue. The Tablet also enables physicians to safely and accurately gauge and monitor the dosage and treatment of each individual patient, something that is essentially impossible to do for patients who administer cannabis by smoking. The Cannabis Tablet provides several benefits: It provides a delivery modality which avoids all the disadvantages of smoking regular tobacco products, including the danger of lung cancer and general damage to the respiratory system. No significant smell. Fixed dosage. Ease of use. The sublingual Tablet will be indicated mainly for chronic pain patients suffering from diseases such as Fibromyalgia or neuropathic pain and PTSD patients. The Tablet dissolves within the mouth allowing it to absorb through the oral mucosa and thus skips the first pass through the liver and has a faster response time than regular tablets or pills. OWC plans to issue additional updates on continued research and further developments in early 2018.